Harvard Bioscience (HBIO) EBITDA (2010 - 2026)

Harvard Bioscience (HBIO) has reported EBITDA for 17 consecutive years, with -$978000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 19.41% year-over-year to -$978000.0 in Q2 2026; TTM through Jun 2026 was -$245000.0, a 99.53% increase from a year earlier, with the FY2025 full-year figure at -$48.6 million, down 682.16% from the prior year.
• EBITDA was -$978000.0 for Q2 2026 at Harvard Bioscience, up from -$1.2 million in the prior quarter.
• Over five years, EBITDA peaked at $4.0 million in Q2 2022 and troughed at -$49.7 million in Q1 2025.
• A 5-year average of -$3.4 million and a median of -$876000.0 in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 2708.37% in 2022 and surged 15445.45% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$457000.0 in 2022, then jumped by 161.71% to $282000.0 in 2023, then tumbled by 96.1% to $11000.0 in 2024, then surged by 15445.45% to $1.7 million in 2025, then slumped by 157.19% to -$978000.0 in 2026.
• The last three EBITDA figures came in at -$978000.0 (Q2 2026), -$1.2 million (Q1 2026), and $1.7 million (Q4 2025), per Business Quant data.